Previously, it was reported that RAD21 overexpression is a marker for poor prognosis in breast [48–50], bladder [51], KRAS mutant colorectal carcinomas [52], and NSCLC [53]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.